Lexaria Bioscience Corp. (LEXX) — Financial statements
Income statement, balance sheet, and cash flow for Lexaria Bioscience Corp. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.71↑52.0% | 0.46↑105.2% | 0.23↓11.4% | 0.26↓64.7% | 0.72 | |
| Cost of Revenue | 0.12↑46.4% | 0.08↓53.0% | 0.17↓17.5% | 0.21↑19.0% | 0.18 | |
| Gross Profit | 0.59↑53.2% | 0.38↑610.3% | 0.05↑15.5% | 0.05↓91.5% | 0.55 | |
| Operating Expenses | ||||||
| R&D Expenses | 8↑249.0% | 2↓35.6% | 4↑99.0% | 2↑45.9% | 1 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 4↑7.1% | 4↑27.3% | 3↓37.9% | 5↓2.1% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 12↑101.0% | 6↓7.7% | 7↑0.6% | 7↑7.9% | 6 | |
| Total Costs & Expenses | 12↑100.3% | 6↓8.9% | 7↑0.1% | 7↑8.2% | 6 | |
| Operating Results | ||||||
| Operating Income | -12↓104.3% | -6↑12.8% | -7↓0.5% | -7↓17.8% | -6 | |
| Depreciation & Amortization | 0.12↑52.1% | 0.08↓47.6% | 0.15↓1.0% | 0.15↓0.5% | 0.15 | |
| EBITDA | -12↓105.8% | -6↑12.7% | -7↑9.3% | -7↓80.2% | -4 | |
| EBIT | -12↓105.1% | -6↑13.5% | -7↑9.1% | -7↓77.3% | -4 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓78.9% | 0.01↓66.9% | 0.04 | 0.00 | 0.00 | |
| Interest Income | 0.00↓78.9% | 0.01↓66.9% | 0.04 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.28↑145.3% | 0.11↓36.5% | 0.18↓79.8% | 0.88↑165.1% | -1 | |
| Other Income / Expenses | -0.28↓145.3% | -0.11↑36.5% | -0.18↑79.8% | -0.88↓165.1% | 1 | |
| Income Before Tax | -12↓105.1% | -6↑13.5% | -7↑9.1% | -7↓77.3% | -4 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -12↓105.1% | -6↑13.5% | -7↑9.1% | -7↓77.3% | -4 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.02 | |
| Net Income | -12↓105.4% | -6↑13.0% | -7↑8.3% | -7↓80.5% | -4 | |
| Bottom-Line Net Income | -12↓105.4% | -6↑13.0% | -7↑8.3% | -7↓80.5% | -4 | |
| EPS (Basic) | -0.66↓40.4% | -0.47↑53.5% | -1.01↑18.5% | -1.24↓34.8% | -0.92 | |
| EPS (Diluted) | -0.66↓40.4% | -0.47↑53.5% | -1.01↑18.5% | -1.24↓34.8% | -0.92 | |
| Weighted Average Shares | 18↑45.3% | 12↑87.2% | 7↑12.4% | 6↑34.0% | 4 | |
| Weighted Average Diluted Shares | 18↑45.3% | 12↑87.2% | 7↑12.4% | 6↑34.0% | 4 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.